Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A new study found that 84% of patients with acute lymphocytic leukemia or their parents over-reported adherence to a regimen of 6-mercaptopurine, an oral maintenance therapy. Forgetfulness was the primary reason for non-adherence, and parental involvement improved adherence rates.
Researchers have developed a potential new anti-cancer drug class that simultaneously inhibits two key molecular targets to maximize therapeutic efficiency and safety. The dual-activity inhibitors target MYC-regulated factors PI3K and BRD4, effectively blocking cancer cell growth and metastasis.
A novel genetic defect in brain tumor cells has been identified by Yale researchers, which renders the cancers sensitive to a specific DNA repair mechanism. The team found that using an FDA-approved drug, olaparib, can cause a significant increase in brain tumor cell death.
Researchers found that long-term soy consumption improves tamoxifen's effectiveness and reduces breast cancer recurrence. However, starting soy intake after diagnosis increases the risk of cancer recurrence.
Researchers at SLU are working on a potential cure for hepatitis B, building on recent advances and partnering with experts in medicinal chemistry. The goal is to develop a new drug that can kill the virus, reducing levels to zero to cure patients.
The number of new therapeutic drugs approved by the FDA was significantly lower in 2016 compared to previous years, with only four cancer drugs receiving approval. Delays in pharmaceutical manufacturing plants and a reduction in cancer drug approvals contributed to this trend.
Researchers used neutron crystallography to visualize the positions and movements of hydrogen atoms in a key enzyme from Helicobacter pylori, which causes stomach cancer. The study provides insights into the enzyme's structure and potential targets for new medications that selectively target H. pylori without harming useful bacteria.
Researchers at OHSU developed a method for quickly mapping single cell genomes, expanding the analysis of cancerous tumors and other diseases. This breakthrough enables precise targeting of cancer cells, offering new avenues for personalized medicine.
The CIViC knowledgebase is an open-access resource that allows anyone to contribute information on cancer mutations. Experts in the field curate and moderate submissions, providing a valuable resource for clinicians to identify important mutations and connect genetic errors with targeted drugs.
New cancer drugs have shown clinical benefit, but disparities in national health technology assessment outcomes hinder patient access. In the UK, prices for some common drugs increased by over 1000% between 2011 and 2016.
A new laboratory technique allows for the indefinite growth of healthy and diseased cells, offering possibilities for living biobanks, personalized medicine, and novel cancer research. The method, known as conditional reprogramming, can grow million new cells in a week without genetic modification.
Researchers at Mount Sinai discovered that specific signals in primary tumors induce dormant cancer cells that can evade chemotherapy. These 'dormant' cells are found in hypoxic regions of the tumor and may lead to disease relapse and poor prognosis.
Researchers found that metformin significantly increased tumor cell apoptosis and altered the cancer microenvironment in patients with head and neck cancer. The study suggests that metformin may make cancer more susceptible to standard therapies and has potential immunotherapeutic effects.
Researchers found inhibiting metabolic enzyme phosphoglycerate mutase 1 (PGAM1) sensitizes tumors to Olaparib, expanding cancer treatment options. Combining PGAM1 inhibitors with Olaparib suppresses tumor growth in BRCA-proficient cancers.
A study of 351 patients with EGFR mutant lung cancer and brain metastases found that radiation therapy followed by targeted medicines resulted in the longest overall survival, with median survival times of 46 months and 30 months respectively. The findings suggest that a more aggressive approach to treating brain metastases may be the ...
Researchers at Huntsman Cancer Institute identified a protein called Macrophage Stimulating Protein (MSP) that causes bone destruction in metastatic breast cancer. A new drug, Ron inhibitor, blocks the activity of MSP, showing promising results in early clinical trials.
Researchers identify proteins that interact with cancer-related proteins at the center of cellular signaling networks, potentially leading to new chemotherapies. These 'first neighbor' proteins have a significant impact on cancer progression and may be useful drug targets.
Researchers have discovered a common weak point in cancer cell metabolism, allowing them to identify drugs that block backup fuel supply routes. This strategy has shown promise against many hard-to-treat cancers, including sarcomas, and may lead to more effective treatments with fewer side effects.
UTA's integrated cancer research program is strengthening with $6 million grants, bolstering basic research, precision medicine, and screening diagnostics. The University aims to make transformative advances in key areas related to cancer while providing top-notch educational experiences for students.
Researchers found that breast cancer tumors evolve to produce their own estrogen supply, making treatments like aromatase inhibitors ineffective. The study, published in Nature Genetics, aims to increase treatment options for patients whose cancer has returned and spread.
Scientists at the University of North Carolina have discovered a promising new avenue for fighting gastrointestinal cancers by unmasking the previously misunderstood gene Gpr182. The study reveals that Gpr182 could be a key regulator of intestinal stem cell proliferation, and its protein code for a potential drug target.
Researchers at UNC have engineered platelets to carry cancer-fighting antibodies, allowing them to target and kill microtumors before they can grow or spread. This innovative approach has shown promising results in animal studies, potentially offering a new hope for patients with recurring cancer after surgery.
A new technique allows scientists to precisely regulate protein production from genes, enabling the design and study of biological systems. This breakthrough can be used to produce desired products, such as medicines, or study disease-related genes, including those implicated in cancer.
The European Society for Medical Oncology advocates for strict adherence to approval standards and accelerated introduction of biosimilars into clinical settings. This move aims to enhance the sustainability and affordability of cancer treatment, with potential benefits including reduced costs and increased accessibility.
Researchers at Case Western Reserve University have uncovered the structure of a cancer cell receptor protein, paving the way for the development of new cancer-fighting drugs. The study identified key binding sites that can be targeted to modulate the protein's function and prevent tumor growth and metastasis.
The DART trial is a national immunotherapy clinical trial testing leading-edge treatments for rare cancers. Patients will receive ipilimumab and nivolumab combination therapy to fight cancer, with the goal of shrinking tumors and evaluating side effects.
A phase 3 trial found regorafenib significantly improved overall survival in patients with advanced hepatocellular carcinoma (HCC), a form of liver cancer. The study showed that regorafenib can improve survival in patients whose HCC progressed during treatment with sorafenib, an existing drug.
The UK Pancreatic Cancer Research Fund has awarded £9 million in grants to five promising research projects aimed at developing new treatments and diagnostic tools for pancreatic cancer. These projects focus on improving clinical trials, investigating innovative therapies, and understanding the genetic causes of chromosomal instability.
A study by TGen has identified aurintricarboxylic acid (ATA) as a compound that can improve drug development against glioblastoma. ATA blocks the chemical cascade that allows glioblastoma cells to invade normal brain tissue and resist chemotherapy and radiation therapy.
A new drug combination that adds chloroquine to targeted treatment has stabilized a 26-year-old brain cancer patient's disease, increasing both quality and quantity of life. The treatment was effective in two other brain cancer patients with similar diseases.
Researchers at Mayo Clinic found that two common cancer-fighting drugs sparked significant weight loss in morbidly obese mice despite a high-fat diet. The study suggests that these drugs can induce the liver to burn off excess fat, reducing obesity. Further research is needed to explore this potential approach for treating morbid obesity.
Researchers found PDX1 plays a complex role in pancreatic cancer, maintaining cell identity in normal cells but contributing to growth once tumor forms. Blocking PDX1 may actually make the cancer more aggressive by selecting for MYC-expressing cells.
A new study reveals significantly better outcomes for patients with metastatic colorectal cancer when combining vemurafenib with standard treatments. The three-drug combination improved progression-free survival rates and tumor response rates compared to traditional therapies.
The Harrington Discovery Institute has selected three 2016 partnership scholars to support groundbreaking research in Alzheimer's disease and blindness. The scholars will receive funding and expert pharmaceutical guidance to advance their discoveries into new medicines.
The Harrington Discovery Institute has announced grant funding for 11 physician-scientists from premiere universities. The recipients will receive up to $700,000 in capital to support the transition of their work into the private sector.
Research in mice suggests that melanomas and other cancers driven by BRAF V600E mutation will grow faster in response to a high-fat diet. Lipid-lowering agents such as statins can slow tumor growth, even on normal diets. The findings highlight the potential of precision diets tailored to individual patients' cancer mutations.
Lutetium-177-Dotatate has shown improved progression-free survival and response rates compared to octreotide alone in patients with advanced disease. The treatment also experienced higher risk of adverse events, but these were manageable and reversible.
A novel treatment targets Graft-Versus-Host Disease (GVHD) by inhibiting Aurora kinase A and JAK2, preserving immune system function. The study shows promising results in mice, potentially offering a more effective and selective prevention strategy.
The Damon Runyon Cancer Research Foundation has awarded nearly $4 million in fellowships to 16 early-career researchers, providing them with independence to pursue innovative projects. The foundation's Breakthrough Scientist Awards also recognize three researchers who have made paradigm-shifting breakthroughs in cancer research.
A University of North Carolina researcher argues that integrating patient-reported symptoms into clinical practice can improve patient outcomes. Despite demonstrated benefits, cost and technology barriers prevent the widespread adoption of electronic symptom reporting.
Researchers at McGill University Health Centre have made a groundbreaking epigenetic modification that may improve treatment options for 15% of patients with head and neck cancer. The discovery could lead to targeted, more effective treatments with fewer side effects.
A Phase 1 clinical trial found that tucatinib significantly improved outcomes in heavily pretreated patients with HER2+ breast cancer. The drug demonstrated stable disease at 24 weeks or more in 27% of patients, showcasing its potential as a game-changing treatment option.
Researchers found that increasing niacin levels boosts NAD compound for energy generation and DNA repair, potentially protecting against Parkinson's. The study suggests repurposing cancer drugs to protect faulty mitochondria in Parkinson's disease.
Researchers have discovered that Dab2 controls a population of fat stem cells that slowly disappears with maturity. This finding may reinforce the importance of steering children away from high-fat diets and lead to new pharmaceutical strategies to combat childhood obesity.
A study found that adults who performed the recommended amount of weekly physical activity in one or two sessions had lower risks for death from all causes, cardiovascular disease, and cancer. The risk reductions were similar among weekend warriors and insufficiently active adults.
Researchers at Mayo Clinic have identified a key drug target, CDK4/6, which regulates the spread of triple-negative breast cancer. The study found that inhibiting this protein with CDK 4/6 inhibitors can prevent the metastasis of triple-negative breast cancer to distant organs.
A study published in JAMA Internal Medicine found that men and women who engage in physical activity on just one or two occasions per week have a lower risk of death from all causes, cardiovascular disease, and cancer. The 'weekend warriors' spent an average of 300 minutes per week doing moderate- to vigorous-intensity physical activity.
Researchers at the University Health Network have discovered a genetic fingerprint that explains why up to 30% of men with localized prostate cancer develop aggressive disease after radiotherapy or surgery. This finding could help clinicians personalize effective treatments from diagnosis, leading to improved cure rates.
Researchers found that tumors shed between seven and 18 mutations in neoantigen-coding genes after developing resistance to immunotherapy drugs. This phenomenon could lead to new ways to improve current cancer immunotherapies.
A study by Yale researchers found that older lung cancer patients can spend an average of one in three days interacting with the healthcare system within the first 60 days after surgery or radiation therapy. Patients with a higher number of medical conditions treated with surgery had the most post-treatment burdens.
Scientists have identified the key molecule YAP that enables cancer cells to break free from their surroundings and continue growing and spreading. By understanding how YAP is controlled in cancer cells, researchers hope to find new ways to treat or prevent the spread of cancer.
Researchers at Penn State have developed a novel biodegradable nanoparticle-based system that utilizes immune cells to target and deliver cancer-fighting drugs directly to tumors. This innovative approach combines the body's natural immune response with targeted delivery, showing promise for effective treatment of various cancers.
Researchers at Michigan State University have discovered a chemical compound that can stop the spread of melanoma cells by up to 90 percent. The compound targets a gene's ability to produce RNA molecules and proteins in melanoma tumors, effectively shutting down the disease's progression.
A study published in Journal of Clinical Oncology found that new therapies for non-small cell lung cancer resulted in a median 1.5-month survival increase, but this gain was largely offset by higher outpatient spending due to the expensive medications.
Researchers at UNC-Chapel Hill have developed a breakthrough technique that uses light to activate a drug stored in circulating red blood cells. This method could drastically reduce the amount of a drug needed to treat disease and thus side effects.
The study reveals how Piperlongumine converts to an active drug that targets and silences the GSTP1 gene, which is often overactive in tumors. This breakthrough provides new hope for developing cancer therapies using natural compounds.
Legumain (LGMN) is a cysteine protease over-expressed in tumor microenvironment, facilitating tumour growth and metastasis. Targeting LGMN directly or as a prodrug activator may offer promising cancer management strategies.
Research found no association between high monitoring (health detail oriented) and more information receipt for RA patients, while high blunting was linked to more info for OA patients. This challenges typical patterns in acute and chronic disease coping literature.
Molecular imaging techniques have the potential to revolutionize cancer diagnosis, monitoring, and treatment by providing non-invasive alternatives to traditional biopsies. By identifying specific biomarkers, these methods can help doctors choose the most effective treatments, minimize side effects, and predict patient outcomes.
A combination of metformin and syrosingopine drives cancer cells to programmed 'suicide' by blocking their energy supply, inhibiting growth and inducing tumor cell death. The treatment shows promise for targeting the energy needs of tumor cells.